Liam Ratcliffe Acquires Shares in Disc Medicine

Liam Ratcliffe recently made a notable move by purchasing 6,212 shares of Disc Medicine, Inc. (NasdaqGM: IRON) on June 18, 2026. This insider transaction did not involve a planned purchase, indicating Ratcliffe's direct interest in the company. The shares were acquired at an unspecified price.

Insider Buying and Selling at Disc Medicine, Inc.

In addition to Liam Ratcliffe's purchase, other insiders were active on June 18, 2026. Nadim Ahmed acquired 5,176 shares, while Rahul Khara, the Chief Legal Officer, bought 7,500 shares at an average price of $14.69. Dr. John Quisel, the CEO, sold 34,000 shares at a price of $70.22 under a planned transaction but also bought back the same number of shares at $9.86.

Other Institutional Activity in Disc Medicine

Several large institutional investors have been adjusting their positions in Disc Medicine. FMR LLC increased its holdings by 136,672 shares, bringing its total to 5,586,894 shares valued at approximately $357.2 million, a 2.5% increase. RA Capital Management added 474,089 shares, marking a 24.0% increase, to hold 2,450,221 shares worth $156.7 million. Wellington Management Group grew its stake by 217,102 shares, a 14.3% boost, for a total of 1,735,376 shares valued at $111.0 million. On the other hand, BlackRock trimmed its position slightly by 1,149 shares to a total of 2,273,831 shares valued at $145.4 million.

Disc Medicine, Inc. Stock Down 11.5%

Shares of Disc Medicine traded at $70.8 on Wednesday. The company has a market cap of roughly $2.7 billion and a forward P/E ratio that is not meaningful due to its lack of profitability. The stock's beta is 2.101, suggesting more volatility compared to the broader market. Over the past year, the stock has ranged from $40.0 to $99.5, with a 50-day moving average of $68.55 and a 200-day moving average of $73.16. Disc Medicine maintains a strong liquidity position with a current ratio of 24.002 and a quick ratio of 23.446.

Analysts Set New Price Targets

Analysts continue to show confidence in Disc Medicine, maintaining a 'strong buy' consensus. Morgan Stanley, on June 16, 2026, upheld its 'buy' rating with a price target of $85.0. Other firms, such as Stifel and Cantor Fitzgerald, have set higher targets of $110.0 and $125.0, respectively. The average target price among analysts is $101.55, with 11 analysts providing opinions.

About Disc Medicine

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. The company focuses on developing novel treatments for serious blood disorders. Its pipeline includes bitopertin for erythropoietic porphyrias, DISC-0974 for anemia associated with myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera. Founded in 2017, Disc Medicine aims to address unmet needs in hematologic health through innovative therapies.

Bottom Line

Liam Ratcliffe's recent purchase of Disc Medicine shares is a sign of confidence in the company's potential. Investors closely watch these insider moves as they can offer insights into the company's prospects. With a strong buy consensus among analysts and a robust pipeline of treatments, Disc Medicine continues to be a company of interest in the biotechnology sector.